Core Insights - Waters Corporation (WAT) is a global leader in analytical instruments and laboratory technologies, with a market cap of $21.4 billion, serving industries such as pharmaceuticals, life sciences, food and beverage, environmental testing, and materials analysis [1] - The company is expected to announce its fiscal Q3 earnings for 2025 on November 4, with analysts predicting a profit of $3.21 per share, a 9.6% increase from $2.93 per share in the same quarter last year [2] - For fiscal 2025, WAT is projected to report a profit of $12.99 per share, reflecting a 9.5% increase from $11.86 per share in fiscal 2024, with further growth expected to $14.18 per share in fiscal 2026 [3] Stock Performance - Over the past 52 weeks, WAT shares have increased by 9.8%, underperforming the S&P 500 Index's 16.9% return but outperforming the Health Care Select Sector SPDR Fund's 2.3% decline [4] - Despite reporting better-than-expected Q2 adjusted EPS of $2.95 and revenue of $771.3 million, WAT shares fell by 1.6% due to investor concerns regarding the planned acquisition of Becton, Dickinson and Company's biosciences and diagnostics unit [5] Analyst Ratings - Wall Street analysts maintain a "Moderate Buy" rating for WAT, with five out of 15 analysts recommending "Strong Buy" and 10 suggesting "Hold," while the mean price target is set at $362.36, indicating a marginal potential upside [6]